Elon Musk's company Neuralink has received approval from Canada to conduct its first clinical trial of a brain implant designed to help paralyzed individuals control digital devices through thought, reports Reuters.
This marks a significant step in the company’s mission to restore lost physical capabilities.
The trial will assess the implant's safety and functionality, focusing on aiding individuals with quadriplegia, a condition causing paralysis in all four limbs.
A hospital within Toronto's University Health Network has been selected to perform the intricate neurosurgical procedure to implant the device.
Neuralink has already implanted its brain chips in two patients in the United States. According to the company, the technology has been effective, with one patient using the implant to play video games and explore 3D design.
These developments highlight the implant's potential to bridge neural activity and external technology.
Founded in 2016, Neuralink’s goal is to use neural signals to enable control of external devices, aiming to restore abilities such as vision, mobility, and speech.
The company envisions its technology revolutionizing how humans interact with digital systems, offering hope for those with severe disabilities.
Earlier this year, Neuralink revealed that its first patient successfully used the implant to move a computer cursor with thought alone.
This breakthrough underscores the transformative potential of brain-machine interfaces for enhancing the quality of life for individuals with neurological impairments.
The Canadian trial represents a critical milestone in Neuralink's journey toward widespread clinical applications.
